GLP1R and metabolic dysfunction-associated steatotic liver disease: Notably, emerging NAFLD therapies—including resmetirom, GLP-1 receptor agonists, and SGLT2 inhibitors—have demonstrated robust efficacy, partly through indirect antioxidant mechanisms.